Cannabis-Dependent People Had Significantly Blunted Dopamine Release in the Brain's Reward System | Research

The takeaway

Using PET brain imaging, researchers found that severely cannabis-dependent people had markedly reduced dopamine release in the striatum (effect size 1.48), and this deficit correlated with inattention, negative symptoms, and poorer cognitive performance.

Readers concerned about the long-term brain effects of heavy cannabis use.

Cannabis-dependent individuals had 1.48 effect size reduction in striatal dopamine release

What the researchers found

Eleven severely cannabis-dependent participants (free of all comorbidities, including nicotine use) and 12 healthy controls underwent PET brain scans before and after amphetamine challenge to measure dopamine release.

Cannabis-dependent participants had significantly lower dopamine release in the striatum (p = 0.002, effect size 1.48), including the associative striatum (ES = 1.39), sensorimotor striatum (ES = 1.41), and the pallidus (ES = 1.16). These are large effect sizes, indicating substantial dopamine system impairment.

Lower dopamine release in the associative striatum correlated with inattention and "negative" symptoms (flat affect, reduced motivation) in the cannabis-dependent group, and with poorer working memory and learning performance in both groups. The deficits persisted even after 5-7 days of standardized inpatient abstinence.

Why it matters

This is one of the most rigorous demonstrations that cannabis dependence is associated with dopaminergic deficits similar to those seen in other addictions. By excluding all comorbidities (including nicotine), the study isolated cannabis's specific contribution. The large effect sizes and the correlation with real-world cognitive and psychiatric symptoms make these findings clinically significant.

The numbers in context

11 cannabis-dependent, 12 controls. Striatal dopamine release: p = 0.002, ES = 1.48. Associative striatum: p = 0.003, ES = 1.39. Sensorimotor striatum: p = 0.003, ES = 1.41. Pallidus: p = 0.012, ES = 1.16. Lower release correlated with inattention, negative symptoms, and cognitive deficits. 5-7 days abstinence before scans.

How the study worked

PET imaging with [11C]-(+)-PHNO before and after oral amphetamine in 11 cannabis-dependent subjects (comorbidity-free, nicotine-free) and 12 healthy controls. Cannabis-dependent participants were inpatient for 5-7 days prior to scans. MRS glutamate measures were also obtained.

What this study cannot tell us

Small sample size (11 per group). 5-7 days of abstinence may not be enough to determine whether deficits are permanent or reversible. The study selected severely dependent participants, so findings may not generalize to moderate or recreational users. Only male participants were included (based on abstract). The cross-sectional design cannot determine whether reduced dopamine release precedes or follows cannabis dependence.

How to read the evidence

Strong evidence from a well-controlled neuroimaging study with large effect sizes, despite small sample.

When this study was published

Published in 2017. Landmark study demonstrating dopaminergic deficits in cannabis dependence.

The bigger picture

The "blunted dopamine" hypothesis of addiction proposes that chronic drug use reduces the brain's ability to release dopamine in response to rewards, driving continued use and contributing to the motivational deficits seen in dependent users. This study provides the first clean evidence that cannabis dependence fits this pattern, placing it alongside alcohol, cocaine, and opioid dependence in terms of dopaminergic impact.

Questions still open

Does dopamine release recover with longer abstinence? Do casual cannabis users show similar (but smaller) deficits? Does the blunted dopamine release explain the amotivational syndrome attributed to chronic cannabis use? Could dopamine-enhancing interventions improve outcomes for cannabis-dependent individuals?

Common questions

Does heavy cannabis use damage the dopamine system?

This study found that severely cannabis-dependent people (with no other substance use including nicotine) had significantly reduced dopamine release in the brain's reward and cognitive processing areas. The large effect sizes indicate substantial impairment. Whether this reverses with prolonged abstinence remains unknown.

Could this explain the "amotivational syndrome" of heavy cannabis use?

The correlation between blunted dopamine release and both negative symptoms (flat affect, reduced motivation) and cognitive deficits is consistent with the amotivational syndrome. Dopamine is critical for motivation and reward processing, and its chronic reduction could underlie the motivational deficits observed in some heavy users.

Read the original research

Deficits in striatal dopamine release in cannabis dependence.

Molecular psychiatry, 22(1), 68-75

View on PubMed ↗Publisher’s paper ↗

Citation

van de Giessen, E; Weinstein, J J; Cassidy, C M; Haney, M; Dong, Z; Ghazzaoui, R; Ojeil, N; Kegeles, L S; Xu, X; Vadhan, N P; Volkow, N D; Slifstein, M; Abi-Dargham, A. (2017). Deficits in striatal dopamine release in cannabis dependence.. Molecular psychiatry, 22(1), 68-75. https://doi.org/10.1038/mp.2016.21